Huami Corp Invests $5 Million in Hyperfine Research D Round

February 10, 2021

Huami Corp. announced that it has invested $5 million in Hyperfine Research’s D round of funding, which closed on February 3, 2021. Funds to support the accelerated application of disruptive MRI technology.

Huami Corporate mission is to connect health with technology, developing both consumer and industrial health technologies. The company believes its miniaturization engineering expertise dovetails with efforts to miniaturize medical imaging technology which can disrupt the locations, applications, and costs of medical imaging.

Hyperfine Research is pioneering MRI imaging with its portable Swoop system, which received FDA 510(K) clearance in August of 2020.

“In the same way that new depth and granularity of data from wearable devices has changed health population management, we see the miniaturization of imaging technology changing the places and speed at which clinicians can evaluate patients,” said Huami’s chief operating officer, Mike Yeung. “We are excited to participate with Hyperfine in support of their mission.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.